Navigation Links
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
Date:10/2/2008

Ph.D., Orexigen President and CEO. "Based on our preclinical data, we believe that OREX-003 has the potential to have an improved metabolic profile and be a more effective long-term option in the management of schizophrenia and a number of related conditions."

About OZ-101

The OZ-101 clinical trial is a double-blind, placebo-controlled clinical trial evaluating the combination of olanzapine plus zonisamide SR versus olanzapine plus placebo in 75 patients with schizophrenia over 16 weeks at nine centers in the U.S. Preclinical studies conducted by Orexigen have demonstrated that zonisamide mitigated both weight gain and elevated blood glucose associated with olanzapine through novel mechanisms. The clinical trial is currently enrolling. More information can be found at http://www.clinicaltrials.gov.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in late-stage of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , 22. Juli 2014 Qforma, ein ... die Ernennung von Marcus Bergler zum General Manager ... hat die europäischen kommerziellen Aktivitäten von Qforma bereits ... sich Qforma anschloss, war er in Positionen als ... als Vertriebsteam-Leiter Deutschland bei IMS Health und als ...
(Date:7/22/2014)... Greenville, SC (PRWEB) July 22, 2014 ... chorus of those who have recognized that the greatest ... inefficient, and far too often needlessly deadly while trying ... the multitude of quasi-experts seeking to transform an enormous ... detail.” , Dr. Williams, in his continuing series of ...
(Date:7/21/2014)... the right amount of tension to a chain of ... to an insulator, according to Rice University scientists. , ... one-dimensional chain of carbon atoms -- by just 3 ... that engineers might find useful for mechanically activated nanoscale ... physicist Boris Yakobson and his colleagues appears in the ...
(Date:7/21/2014)... 2014  Mike Patterson, CEO of Graphene Frontiers, ... Series Seed B funding to finance production of ... life science, defense, intelligence, and environmental industries.  A ... round and was joined by R2M Investments.  Return ... , "This round of funding will ensure Graphene ...
Breaking Biology Technology:Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Carbyne morphs when stretched 2Carbyne morphs when stretched 3Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2
... and TOKYO, Aug. 15, 2011 A new post-hoc ... TRITON-TIMI 38 study – those identified as the "core ... (in combination with aspirin) was associated with a 26 ... of cardiovascular death, myocardial infarction or stroke, compared to ...
... team of researchers from the National Institute of ... the University of Maryland has made nano-sized sensors ... paints, cleaners, pesticides and other productsthat offer several ... room-temperature operation and the ability to detect one ...
... and portable detector that takes just fifteen minutes to ... being developed by US researchers. The technology amplifies any ... the presence of just 40 microscopic cells of the ... as anthrax, is a potentially lethal microbe that might ...
Cached Biology Technology:Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8Nanowire-based sensors offer improved detection of volatile organic compounds 2Nano detector for deadly anthrax 2
(Date:7/22/2014)... as a world-famous vacation spot with natural tourism resources, a ... The Korea Institute of Geoscience and Mineral Resources (KIGAM) indicated ... volcanic eruption was evident 5,000 years ago. That is the ... spewed out of a volcano 5,000 years ago in the ... the whole peninsula. , The research team led by Dr. ...
(Date:7/22/2014)... prevent their daughters from breeding, and kill their grandchildren ... desert creatures which live in groups with a dominant ... alpha female can flourish when it maintains the sole right ... life, also found in many animals such as ants and ... Dominant meerkats control breeding within their group through violence, by ...
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... (HLB), meaning "yellow shoot disease" in Chinese and ... the most destructive disease threatening the citrus industry ... are desired to control it. A new study, ... contributing factor in symptom expression for citrus Huanglongbing ...
... The Alfred P. Sloan Foundation is pleased to announce ... as recipients of Sloan Research Fellowships for 2013. ... to early-career scientists and scholars whose achievements and potential ... scientific leaders. "The Sloan Research Fellows are the ...
... Research Centre at Saint Mary,s Hospital and The University ... causing an inherited form of tumour, known as spinal ... Meningiomas are the commonest form of tumour affecting the ... surgery and do not recur. Occasionally people can develop ...
Cached Biology News:Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 2Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 3Sloan Foundation announces 2013 Sloan Research Fellows 2Researchers in Manchester find genetic key to preventing spine tumors 2
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic acid stain has also found uses ... bandshift assays. A 500 µL unit size (S-7563) ...
... cross-linking techniques are defined by the author ... Wong. This valuable hardcover guide includes hundreds ... application references. More than 300 pages detail ... conjugate preparation from selection and design ...
... protein separation by two-dimensional electrophoresis (2D-PAGE), ... package from Bio-Rad and protein identification ... to meet customers requirements regarding experimental ... format of the results permanent contact ...
... reagents for immune complex disruption (ICD) of ... using a combination of low pH and ... transferred to microplate wells which are coated ... to HIV-1 p24. The immobilized monoclonal antibody ...
Biology Products: